TreatmentEGFR Lung Cancer(มะเร็งปอด ชนิดไม่เซลล์เล็ก (NSCLC)
Brand name: Giefoni,
Generic name: Gefitinib (250mg )
Giefoni is a tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) where epidermal growth factor receptor (EGFR) exon 19 is absent or exon 21 (L858R) replaces the mutant type.
Medication limitations: the safety and efficacy of Giefoni for EGFR mutations other than exon 19 deletion or exon 21 (L858R) replacement mutations have not been determined
[How to take the drug]
1. Therapy period
Recommended dosage: 250mg, taken orally, once daily; Not with food or with food.
2. Dosage form specification:
- Tablet, 250mg.
[Warnings and precautions]
● Interstitial lung disease (ILD) : there may be ILD during giffornia. If the ILD is confirmed, the medication is terminated.
● Hepatotoxicity: regular liver function testing. The presence of elevated ALT and/or AST at level 2 or higher requires a drug break. Discontinue medication if severe liver damage occurs
●Gastrointestinal perforation: discontinue medication if gastrointestinal perforation occurs.
●Diarrhea: medication suspension is required for diarrhea of grade 3 or higher.
●Eye diseases include keratitis: severe or worsening eye diseases include signs and symptoms of keratitis requiring medication discontinuation, and discontinuation of medication for prolonged ulcerative keratitis.
●Cowhide and exfoliating skin diseases: drug suspension is required for skin reactions or peeling at grade 3 or higher.
●Embryonic toxicity: may cause fetal damage. Effective contraceptive measures are recommended to avoid potential fetal risks.
More than 20 percent of the most common side effects in the placebo group were skin reactions and diarrhea.
[How to store the drug]
Keep this medicine at dark, cool and dry place.